Latest Safety News

RemSense Technologies closed FY2025 with a positive EBITDA and expanding virtualplant platform usage among major clients, setting the stage for significant growth in FY2026. The company’s strategic hires and new contracts highlight its rising footprint in industrial digital transformation.

Citigold Corporation Limited reports steady progress in exploration and mine design at its Charters Towers Gold Project, while actively pursuing funding partnerships to restart operations.

Altech Batteries confirms the safety and durability of its CERENERGY® sodium-nickel-chloride battery technology through rigorous testing, while its Silumina Anodes™ pilot plant in Germany achieves a 50% capacity increase. An independent DNV study endorses the technology’s promising future.

Alterity Therapeutics has secured U.S. FDA Fast Track designation for its drug ATH434 targeting Multiple System Atrophy, supported by promising Phase 2 clinical trial data showing slowed disease progression and a solid safety profile.

Tanami Gold NL reported significant drilling progress at its Central Tanami Project with promising gold intercepts at Jims Gold Mine, while Mount Gibson Iron moves to acquire a 50% stake in the joint venture.

Element 25 Limited has locked in AU$50 million in senior debt from the Northern Australia Infrastructure Facility to expand its Butcherbird manganese project, while advancing its US battery-grade manganese refinery with significant government grants and patent protections.

Syrah Resources has resumed production at its Balama graphite mine after a year-long halt and is advancing sales at its US Vidalia anode material facility, supported by new US tariffs on Chinese imports and a $70 million equity raise.

Syntara Limited reports encouraging Phase 2 data for its lead drug amsulostat in myelofibrosis, secures FDA Fast Track status, and expands clinical programs into myelodysplastic syndrome and keloid scars.

Cynata Therapeutics is advancing three pivotal clinical trials targeting acute Graft versus Host Disease, osteoarthritis, and kidney transplantation, with major results expected through early 2026. The company maintains a solid cash position supporting its clinical pipeline and strategic growth.

Prescient Therapeutics has secured FDA Fast Track designation for PTX-100 in treating relapsed Cutaneous T-Cell Lymphoma and dosed the first patient in its Phase 2a trial, supported by a recent $6.8 million capital raise.

Aurora Labs has advanced its micro gas turbine program with key test bench upgrades, a significant Defence grant, and strategic partnerships, positioning itself for international defence market entry.

Core Lithium has repositioned its Finniss Lithium Project as a low-cost underground operation with a 20-year mine life, slashing operating costs by a third and boosting production capacity. The company is advancing strategic funding while unlocking flexibility through a key offtake agreement termination.